Treatment progress of inherited epidermolysis bullosa.

IF 4 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Expert Opinion on Biological Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-30 DOI:10.1080/14712598.2025.2525860

Wen-Ming Wang, Hao Feng, Qian-Nan Jia, Hong-Zhong Jin

{"title":"Treatment progress of inherited epidermolysis bullosa.","authors":"Wen-Ming Wang, Hao Feng, Qian-Nan Jia, Hong-Zhong Jin","doi":"10.1080/14712598.2025.2525860","DOIUrl":null,"url":null,"abstract":"Introduction: Inherited epidermolysis bullosa (EB) is a family of rare-inherited dermatoses that result in mucocutaneous fragility and blister formation inducible by minor trauma. Clinically, EB mainly presents as increased skin fragility with trauma-induced blisters and erosions, combined with extracutaneous manifestations and their complications in other epithelialized organs. No cure for inherited EB is currently available. Treatment of inherited EB is mainly supportive, aiming to reduce patients' pain and itching.Areas covered: Some advances in the treatment of inherited epidermolysis bullosa have recently been achieved, including topical drug treatment, systemic drug treatment, gene-based therapy, and cell-based therapy. This review focuses on the treatment progress of inherited epidermolysis bullosa. PubMed was searched up to February 2025 to identify relevant studies on inherited EB.Expert opinion: Emerging advances of therapies in gene-based therapy and cell-based therapy can partially address the symptoms of EB and provide hope for the patients.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"847-857"},"PeriodicalIF":4.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Biological Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14712598.2025.2525860","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Inherited epidermolysis bullosa (EB) is a family of rare-inherited dermatoses that result in mucocutaneous fragility and blister formation inducible by minor trauma. Clinically, EB mainly presents as increased skin fragility with trauma-induced blisters and erosions, combined with extracutaneous manifestations and their complications in other epithelialized organs. No cure for inherited EB is currently available. Treatment of inherited EB is mainly supportive, aiming to reduce patients' pain and itching.

Areas covered: Some advances in the treatment of inherited epidermolysis bullosa have recently been achieved, including topical drug treatment, systemic drug treatment, gene-based therapy, and cell-based therapy. This review focuses on the treatment progress of inherited epidermolysis bullosa. PubMed was searched up to February 2025 to identify relevant studies on inherited EB.

Expert opinion: Emerging advances of therapies in gene-based therapy and cell-based therapy can partially address the symptoms of EB and provide hope for the patients.

查看原文本刊更多论文

遗传性大疱性表皮松解症的治疗进展。

简介：遗传性大疱性表皮松解症（EB）是一种罕见的遗传性皮肤病家族，其结果是由轻微创伤诱导的皮肤粘膜脆性和水疱形成。临床上，EB主要表现为皮肤脆性增加，外伤性水疱和糜烂，并伴有皮外表现及其在其他上皮化器官的并发症。目前还没有治愈遗传性EB的方法。遗传性EB的治疗以支持性为主，旨在减轻患者的疼痛和瘙痒。涵盖领域：最近在遗传性大疱性表皮松解症的治疗方面取得了一些进展，包括局部药物治疗、全身药物治疗、基因治疗和细胞治疗。本文就遗传性大疱性表皮松解症的治疗进展作一综述。检索截至2025年2月的PubMed，以确定遗传性EB的相关研究。专家意见：基因疗法和细胞疗法的新进展可以部分解决EB的症状，为患者带来希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Biological Therapy 医学-生物工程与应用微生物

CiteScore

8.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease. The journal welcomes: Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine Drug evaluations reviewing the clinical data on a particular biological agent Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points.